trial

Effect of Varenicline on Cognitive Function in Cigarette Smokers With Schizophrenia

NCTId NCT01093365
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 58 (actual)
Sponsored by Centre for Addiction and Mental Health
Primary completion 2016-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
58 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Quadruple
Start
2010-03
Primary completion
2016-08
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
Varenicline

Sponsors

Centre for Addiction and Mental HealthLead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Collaborator

Investigators

1
Tony P George, MD, FRCPCPrincipal Investigator

Sites

1 total
Toronto, Canada

Linked catalysts

1
Effect of Varenicline on Cognitive Function in Cigarette Smokers With Schizophre — primary completion2016-08

Facts & assertions

4 sourced
Enrollment
58
Phase
PHASE2
Primary Completion Date
2016-08
Status
COMPLETED
relationships
The graph out of here
drug
Varenicline
drug
lead_sponsor
Centre for Addiction and Mental Health
company
collaborator
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
company
indication
Smoking
indication
Schizoaffective Disorder
indication
Psychotic Disorders
indication
investigator
Tony P George, MD, FRCPC
person